local_hospital

Saint Luke's Radiation Oncology Network

Address
lock Available on a paid plan

Radiation Oncology and Head & Neck Cancer Research

At Saint Luke's Radiation Oncology Network in Dublin, a major focus is on head and neck cancers within oncology and radiation therapy. Trials are studying advanced disease, including oropharyngeal cancer and squamous cell carcinoma of the head and neck, with the goal of improving survival, reducing recurrence, and finding better treatment combinations.

  • Testing whether adding new therapies to radiotherapy can improve outcomes in locally advanced head and neck cancer
  • Comparing treatment approaches to extend survival in oropharyngeal cancer
  • Evaluating side effects, swallowing function, and quality of life alongside cancer control

This research also explores how to balance effectiveness with tolerability, especially for older patients and those with advanced disease.

Prostate Cancer and Male Urogenital Diseases

Another important area at this clinical research site is prostate cancer, spanning localized high-risk disease and metastatic hormone-sensitive prostate cancer. The studies are examining whether adding new hormone-based treatments to standard care can improve survival and delay progression.

  • Assessing treatment strategies for localized very high-risk prostate cancer
  • Studying approaches for metastatic hormone-sensitive prostate cancer
  • Testing whether new combinations can improve cancer control when used with androgen deprivation therapy and radiation therapy

These trials aim to strengthen long-term disease control while supporting better outcomes for men with aggressive prostate cancer.

Solid Tumours and Recurrence Prevention

The site is also involved in broader cancer research across neoplasms, including studies in breast cancer, colon cancer, rectal cancer, stomach cancer, and oesophageal cancer. This work focuses on helping prevent recurrence and improving survival after standard treatment.

  • Exploring whether aspirin use after treatment can reduce the chance of cancer returning
  • Studying survival outcomes in people with common non-metastatic solid tumours
  • Supporting research into long-term disease control after primary therapy

These investigations reflect a strong interest in finding practical ways to improve outcomes across several common cancers.

Therapeutics and Treatment Optimization

Within analytical, diagnostic and therapeutic techniques and equipment, the trials at Saint Luke's Radiation Oncology Network are refining how cancer treatment is delivered. The emphasis is on making established therapies more effective and less toxic through better treatment selection and combination strategies.

  • Comparing different cisplatin and radiation schedules for head and neck cancer
  • Evaluating treatment intensification approaches for patients with higher-risk disease
  • Measuring outcomes such as survival, recurrence, and treatment-related side effects

Overall, the research portfolio shows a clear commitment to improving the effectiveness, safety, and quality of cancer care across multiple disease areas.

Site Overview

assignment
7
connected trials
corporate_fare
4
sponsors
science
11
IMPs

Activity Indicator

Last 6 months

0
Trials started
-100% vs previous period.
1
Trials started 6–12 months ago
7
Total trials linked
Active
trending_downDeclining-100%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
2
Sponsors (total)
4
Active sponsors
2

Sponsor Network

Top 2 by active trials.

lock +1 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +1 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 45 other sites in Ireland

description
Trial volume
7
Outperforms 67% of sites
public
Therapeutic diversity
4areas
Outperforms 71% of sites
groups
Sponsor diversity
4sponsors
Outperforms 58% of sites

Therapeutic Area Benchmark — Ireland

Select a therapeutic area to compare against other sites in Ireland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Ireland

Market Share

Country: Ireland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Saint Luke's Radiation Oncology Network

lock Showing 1 of 7 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Randomized Controlled Trial Evaluating the Efficacy of Lutetium (177Lu) Vipivotide Tetraxetan in Patients with Metastatic Hormone-Sensitive Prostate Cancer Receiving Androgen Deprivation TherapyUniversity College LondonPhase IIIRecruitingApr 2026

IMP list

lock Showing 1 of 11 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Cisplatin2Unknown2024-12-092025-01-21

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.